JP2019511553A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511553A5
JP2019511553A5 JP2018554360A JP2018554360A JP2019511553A5 JP 2019511553 A5 JP2019511553 A5 JP 2019511553A5 JP 2018554360 A JP2018554360 A JP 2018554360A JP 2018554360 A JP2018554360 A JP 2018554360A JP 2019511553 A5 JP2019511553 A5 JP 2019511553A5
Authority
JP
Japan
Prior art keywords
cancer
composition
inhibitor
composition according
dyrk1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554360A
Other languages
English (en)
Japanese (ja)
Other versions
JP7278776B2 (ja
JP2019511553A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027734 external-priority patent/WO2017181087A1/en
Publication of JP2019511553A publication Critical patent/JP2019511553A/ja
Publication of JP2019511553A5 publication Critical patent/JP2019511553A5/ja
Application granted granted Critical
Publication of JP7278776B2 publication Critical patent/JP7278776B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554360A 2016-04-15 2017-04-14 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ Active JP7278776B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323583P 2016-04-15 2016-04-15
US62/323,583 2016-04-15
PCT/US2017/027734 WO2017181087A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis

Publications (3)

Publication Number Publication Date
JP2019511553A JP2019511553A (ja) 2019-04-25
JP2019511553A5 true JP2019511553A5 (enExample) 2020-06-11
JP7278776B2 JP7278776B2 (ja) 2023-05-22

Family

ID=60039311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554360A Active JP7278776B2 (ja) 2016-04-15 2017-04-14 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ

Country Status (11)

Country Link
US (3) US10314843B2 (enExample)
EP (1) EP3443351A4 (enExample)
JP (1) JP7278776B2 (enExample)
KR (2) KR102494172B1 (enExample)
CN (1) CN109313197A (enExample)
AU (2) AU2017248807A1 (enExample)
BR (1) BR112018071023A2 (enExample)
CA (1) CA3020978A1 (enExample)
IL (2) IL292475A (enExample)
MX (2) MX2018012508A (enExample)
WO (1) WO2017181087A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322128B2 (en) 2016-04-15 2019-06-18 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2475368B1 (en) * 2009-09-11 2014-12-17 Amgen, Inc N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US9446044B2 (en) * 2011-08-19 2016-09-20 Diaxonhit DYRK1 inhibitors and uses thereof
FR2993317B1 (fr) 2012-07-16 2014-08-15 Snecma Carter de turbomachine dans un materiau composite et procede de fabrication associe
RU2016117729A (ru) * 2012-10-10 2017-11-10 Фелиситекс Терапеутикс, Инк. Терапия рака путем таргетинга покоящихся раковых клеток
EA201600003A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
US9566280B2 (en) * 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
MA39763A (fr) 2014-03-20 2017-01-25 Samumed Llc Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
US20170304313A1 (en) 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
CN108135871B (zh) * 2015-07-23 2022-11-04 博蔚医药生物科技股份有限公司 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物
US10322128B2 (en) 2016-04-15 2019-06-18 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors

Similar Documents

Publication Publication Date Title
JP2019511553A5 (enExample)
IL292475A (en) Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
JP2019511554A5 (enExample)
JP2010526098A5 (enExample)
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
MX372716B (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen.
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
PH12015502563A1 (en) Bipyrazole derivatives as jak inhibitors
EA201490357A1 (ru) Индазолы
NZ626942A (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
JP2021501208A5 (enExample)
CL2013003073A1 (es) Compuestos derivados de pirrolotriazinona o imidazotriazinona, inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; utiles en el tratamiento de enfermedades respiratorias, inflamatorias, autoinmune, neurologica, cancer, entre otras.
MY155639A (en) 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
MX375724B (es) Compuestos y métodos para la inhibición de jak.
JP2017511321A5 (enExample)
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
JP2010528021A5 (enExample)
PE20130246A1 (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SINTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
EA201890094A1 (ru) Производные полициклических амидов в качестве ингибиторов cdk9
AR098776A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
MX2017005281A (es) Etil n-boc piperidinil pirazolo piridonas como inhibidores de janus quinasa.
EA201790603A1 (ru) Ингибиторы гистондеметилазы
JP2015520770A5 (enExample)
MY178136A (en) Novel imidazopyridazine compounds and their use
CY1118559T1 (el) 2,6-διαμινο-πυριμιδιν-5-υλο-καρβοξαμιδια ως αναστολεις των κινασων συκ ή jak